Bedrijfsoverzicht
Catheter Precision, Inc. is a specialized entity within the healthcare sector that focuses on the design, manufacturing, and sale of medical technologies for cardiac electrophysiology in the United States. The company's primary commercial offering is the View into Ventricular Onset System, a non-invasive imaging solution designed to facilitate 3D cardiac mapping and assist in the precise localization of cardiac structures. Operating within the medical devices industry, the firm targets professionals and institutions requiring advanced diagnostic tools for heart rhythm management. With a total market capitalization of $3.20 million and annual revenue of $819,000, the company currently operates as a micro-cap entity with no disclosed employee count. These valuation figures indicate that the firm is in an early-stage development phase, where capital allocation is heavily weighted toward research and product development rather than broad-scale commercial expansion or profitability. The low market cap relative to its revenue suggests a high level of risk associated with the company's growth trajectory and its ability to transition from product innovation to sustainable market dominance.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $819,000, yet it posted a net income of $-17,183,000 and an EBITDA of $-10,066,000 during the same period. The substantial discrepancy between the positive revenue of $819,000 and the severe net loss of $-17,183,000 reveals an extremely fragile cost structure where operating expenses and other costs far exceed gross profits. Free cash flow stands at $-4,021,750, which indicates that the company is burning through its limited cash reserves to fund operations and potentially fund future product launches or clinical trials. While the gross margin is robust at 92.3%, the operating margin is an anomalous -1204.2%, signaling that overhead costs, likely driven by R&D and regulatory expenses, are disproportionately high relative to sales. The profit margin is listed at 0.0%, confirming that the company has not yet achieved profitability despite generating revenue from its core business. On the balance sheet, cash holdings of $88,000 are significantly outweighed by total debt of $3.85 million, resulting in a debt-to-equity ratio of 57.83. This leverage profile suggests the balance sheet is highly leveraged and potentially vulnerable to interest rate fluctuations or a downturn in operating cash flow. Liquidity is constrained, evidenced by a current ratio of 0.10, which implies the company possesses less than one-third of the current assets needed to cover its short-term liabilities without raising additional capital. Return on equity is -192.3% and return on assets is -34.9%, metrics that reveal management has yet to generate value for shareholders or efficiently utilize its asset base to produce earnings.
Waarderingsbeoordeling
Valuation metrics for Catheter Precision, Inc. present a complex picture due to the lack of traditional earnings multiples. The trailing P/E ratio is N/A, while the forward P/E is reported as -0.32, implying that the market prices the stock based on anticipated future earnings rather than current performance. The price-to-book ratio stands at 0.45, indicating that the market values the company at less than half of its book value, which often reflects investor skepticism regarding the quality of assets or the ability to convert assets into cash. The price-to-sales ratio is 3.91, and the EV/EBITDA is -0.65; these alternative metrics suggest the company is valued on revenue potential rather than earnings power, a common characteristic for pre-profitable medical device firms. The stock has traded between a 52-week low of $0.85 and a high of $15.77, meaning the current price sits significantly below the recent volatility peak and reflects a correction from its yearly highs. The beta value is 0.26, which indicates that the stock's price volatility is substantially lower than the broader market, suggesting it may move less in response to general market swings but carries idiosyncratic risk specific to the company's operational milestones.
Growth & Income
Revenue growth year-over-year accelerated to 59.7%, demonstrating strong top-line expansion likely driven by the adoption of the View into Ventricular Onset System or increased sales volume. However, earnings growth is N/A due to the company's significant losses, which means earnings are not growing at a pace that can offset the rapid revenue increase, highlighting the heavy burn rate required to sustain current operations. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, all financial resources are retained within the company to fund further research, development, and capital expenditures rather than being distributed to shareholders. This reinvestment strategy is typical for companies in the medical device sector that are prioritizing long-term product pipeline growth over immediate income generation. The overall growth and income profile is defined by aggressive revenue expansion coupled with deep losses and no dividend income, requiring continuous external financing to maintain operations and achieve future profitability.